近日，成大生物发布公告称，公司的全资子公司成大生物（本溪）有限公司近日收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，批准流感病毒裂解疫苗（高剂量）开展临床试验。 该疫苗的注册分类为预防用生物制品3.2类，适用于60周岁及以上老年人群，用于预防疫苗相关型别的流感病毒引起的 流行性感冒。 公告中提到，该疫苗的有效成分是常规剂量流感的四倍，国际市场上已有多个国家和地区获批上市，具有较高的市场 需求。 （成大生物公告） ...

Group 1 - Major shareholder Han Yuanfu of Dayuan Pump Industry plans to reduce his stake by up to 3%, totaling no more than 5.595 million shares [1] - Hainan Highway, a shareholder of Haikou Group, intends to increase its stake in the company by no less than 40 million yuan and no more than 50 million yuan [2] - China Communications Construction Company signed new contracts worth 1.883672 trillion yuan in 2025, a year-on-year increase of 0.13% [3] Group 2 - The controlling shareholder of Quzhou Development proposed to repurchase shares worth between 100 million and 200 million yuan [4] - Shareholder Huang Song of Huibo Pu plans to reduce his stake by up to 1%, totaling no more than 1.3372 million shares [5] - The board secretary of Fusenmei has had his detention lifted and is now under investigation, allowing him to resume his duties [6] Group 3 - YN Holdings clarified that its investment target does not belong to the sectors of computing chip manufacturing, computing leasing, or cloud services [7] - Shareholder Euro Star Diamond plans to reduce its stake in Laishen Tongling by up to 3%, totaling no more than 1.029 million shares [8] - Shareholder Zhu Guangkui of Demar Technology plans to reduce his stake by up to 3%, totaling no more than 791.24 million shares [10] Group 4 - Newnow's subsidiary received approval for clinical trials of drug SYS6023 for breast cancer treatment [11] - Ruipubio plans to invest 295 million yuan to establish a merger and acquisition industry fund focusing on animal health and biomedicine [12] - Shareholder Ningbo Hutong plans to reduce its stake in Huitong Energy by up to 1%, totaling no more than 206.28 million shares [13] Group 5 - Chengda Bio's high-dose influenza virus vaccine has received approval for clinical trials [14] - Kang En Bei's subsidiaries participated in the national centralized procurement process, with selected drugs expected to generate 385 million yuan in sales in 2024 [15] - Weitang Industrial signed a strategic cooperation framework agreement with Amphenol to enhance product development and market collaboration [16] Group 6 - Terui De is the first candidate for a 137 million yuan EPC general contracting project [17] - Chen Zhan Optoelectronics plans to invest 650 million yuan to establish an overseas smart manufacturing base [19] - Zhang Yi Technology's AI short drama business revenue is expected to account for no more than 1% of total revenue in 2025 [20] Group 7 - Jiangshan Co. plans to reduce its stake by up to 3%, totaling no more than 4.3308 million shares [21] - Xie Chuang Data plans to procure servers from multiple suppliers, with a total expected expenditure of no more than 11 billion yuan [22] - Huaming Equipment is planning to issue H-shares and list on the Hong Kong Stock Exchange [23] Group 8 - Wenzhou Hongfeng plans to raise no more than 450 million yuan through a private placement for expansion projects [24] - Yingkerui plans to raise no more than 379 million yuan for various projects including smart power supply systems [25] - Jingrui Electric Materials plans to invest 600 million yuan to build a key materials base for the integrated circuit manufacturing industry [26] Group 9 - Beijing Bank's chairman resigned due to age [27] - Youkeshu's actual controller plans to increase his stake by no less than 50 million yuan and no more than 100 million yuan [28] - Hanbo High-tech's subsidiary plans to acquire assets to enter the wet electronic chemicals industry [29] Group 10 - Jia Mei Packaging clarified that its capital operations related to Magic Atom will be independent of the listed company [30] - International Composite Materials confirmed that electronic-grade glass fiber is a key raw material for PCBs [31] - Zhongyin Fashion plans to procure hardware simulation accelerators for 9.385 million USD [32] Group 11 - Haohai Biotechnology's shareholder plans to reduce his stake by up to 0.4337% [33] - United Optoelectronics plans to sign a framework contract with Lingzhi Cloud Creation for robot assembly services [34] - Qianfang Technology's major shareholder plans to reduce its stake by up to 1.5%, totaling no more than 2.36507 million shares [35] Group 12 - Xiamen Airport plans to acquire 100% of Zhaoxiang Technology for 1.193 billion yuan [36] - Tuoshan Heavy Industry plans to acquire 51% of Xin Kaiyuan for 219 million yuan [38] - Shenkai Co. plans to repurchase shares worth between 40 million and 80 million yuan [39] Group 13 - Hushun Co. plans to invest 3.3 billion yuan in a high-end PCB production project [40] - Zhengzhou Bank appointed Wang Sentao as vice president, pending regulatory approval [41]

Core Viewpoint - The approval of a high-dose influenza virus split vaccine by Chengda Biological's subsidiary marks a significant step in addressing the growing demand for influenza prevention among the aging population in China [1][2] Group 1: Vaccine Approval and Characteristics - Chengda Biological's high-dose influenza virus split vaccine has received approval from the National Medical Products Administration to conduct clinical trials [1] - The vaccine is developed using WHO-recommended strains and has an antigen content four times that of standard-dose influenza vaccines, targeting individuals aged 60 and above [1] Group 2: Market Context and Implications - The aging population in China is increasing, leading to a heightened demand for effective influenza prevention strategies among the elderly [2] - Currently, there are no high-dose influenza vaccines approved for sale in China, making this clinical trial approval a crucial step for the company in responding to health aging strategies [2] Group 3: Future Development and Strategic Goals - Chengda Biological aims to continue its innovation-driven development strategy, enhancing its technological platform and the ability to translate research outcomes into products [2] - The company plans to advance the research and development of influenza vaccines and other key projects to improve public health and contribute to the high-quality development of China's biopharmaceutical industry [2]

证券代码：688739 证券简称：成大生物 公告编号：2026-012 辽宁成大生物股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 12 日 （二） 股东会召开的地点：辽宁省沈阳市浑南区新放街 1 号 辽宁成大生物股份 有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 275 | | --- | --- | | 普通股股东人数 | 275 | | 2、出席会议的股东所持有的表决权数量 | 242,892,071 | | 普通股股东所持有表决权数量 | 242,892,071 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 58.3244 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.3244 | （四 ...

（记者 王晓波） 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 每经AI快讯，成大生物2月12日晚间发布公告称，辽宁成大生物股份有限公司全资子公司成大生物（本 溪）有限公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准流感病毒 裂解疫苗（高剂量）开展临床试验。鉴于疫苗产品研发周期较长、审批环节较多，易受诸多不确定性因 素影响，敬请广大投资者审慎决策，注意投资风险。 ...

本溪子公司申报的流感病毒裂解疫苗（高剂量），系用世界卫生组织（WHO）推荐的甲型和乙型流行 性感冒病毒株分别接种鸡胚，经培养、收获病毒液、纯化、病毒裂解、灭活后制成，有效成分是常规剂 量流感的四倍。 格隆汇2月12日丨成大生物(688739.SH)公布，公司全资子公司成大生物（本溪）有限公司（以下简 称"本溪子公司"）于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》（通知书编 号：2026LP00405），批准流感病毒裂解疫苗（高剂量）开展临床试验。 ...

格隆汇2月12日丨成大生物(688739.SH)公布，根据公司《公司章程》相关规定，公司董事会增设联席董 事长1人。本次第五届董事会第二十七次会议以9票赞成、0票反对、0票弃权的表决结果，审议通过《关 于选举公司第五届董事会联席董事长的议案》，同意选举徐飚先生为公司第五届董事会联席董事长，任 期自本次董事会审议通过之日起至第五届董事会任期届满之日止。徐飚先生担任联席董事长期间，仍兼 任公司董事及战略委员会委员职务。 ...

辽宁恒信(沈阳)律师事务所 关于辽宁成大生物股份有限公司 2026年第一次临时股东会 法律意见书 致:辽宁成大生物股份有限公司 辽宁恒信(沈阳)律师事务所〈以下简称"本所"〉接受辽宁成大生物股份 有限公司(以下简称"公司")的委托,指派孙颖律师、李宪锋律师(以下简称 "本所律师")出席公司2026年第一次临时股东会(以下简称"本次股东会"), 对本次股东会的合法性进行见证。 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和 国证券法》《上市公司股东会规则》(以下简称"《股东会规则》")等有关法 律、法规和规范性文件以及《辽宁成大生物股份有限公司章程》(以下简称"《公 司章程》")等有关规定,本所律师审查了公司提供的如下文件: 1. 公司现行的《公司章程》; 本所律师仅对本次股东会的召集、召开程序、出席会议人员资格、召集人资 格及会议表决程序、表决结果是否符合《公司法》《股东会规则》等法律、法规、 规范性文件及《公司章程》《股东会议事规则》的规定发表意见,不对本次股东 会审议的议案内容以及这些议案所表述的事实或数据的真实性及准确性发表意 见。 本法律意见书仅供公司本次股东会相关事项的合法性之 ...

根据公司《公司章程》相关规定，公司董事会增设联席董事长 1 人。 本次第五届董事会第二十七次会议以 9 票赞成、0 票反对、0 票弃权的表决 结果，审议通过《关于选举公司第五届董事会联席董事长的议案》，同意 选举徐飚先生（简历详见附件）为公司第五届董事会联席董事长，任期自 本次董事会审议通过之日起至第五届董事会任期届满之日止。徐飚先生担 任联席董事长期间，仍兼任公司董事及战略委员会委员职务。 二、本次选举对公司的影响 徐飚先生自 2025 年 8 月担任公司董事以来，勤勉尽责、恪尽职守，为 公司管理与发展出谋献策。徐飚先生专业功底深厚，拥有丰富的资本市场 实践经验与出色的公司管理能力，担任联席董事长后将有效推动控股股东 与公司业务发展深度协同，为公司战略执行及经营发展提供重要支持。当 选联席董事长后，徐飚先生将协助统筹董事会日常工作，推动公司生物医 药产业整合的布局与落地，打造公司第二增长曲线，提升公司价值。 本次选举是公司优化治理结构、完善决策机制、推动战略落地的重要 举措，将充分发挥徐飚先生的专业优势与资源整合能力，有助于进一步提 升公司规范运作水平与核心竞争力，夯实公司长期稳定发展基础。 证券代码：68 ...

证券代码：688739 证券简称：成大生物 公告编号：2026-011 申请事项：境内生产药品注册临床试验 申请人：成大生物（本溪）有限公司、辽宁成大生物股份有限公司。 通知书编号：2026LP00405 审批结论：根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》 及有关规定，经审查，2025 年 11 月 21 日受理的流感病毒裂解疫苗（高剂量）符 合药品注册的有关要求，同意于 60 周岁及以上老年人群开展用于预防疫苗相关型 别的流感病毒引起的流行性感冒的临床试验。 辽宁成大生物股份有限公司 关于流感病毒裂解疫苗(高剂量)获得药物临床试验批 准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 辽宁成大生物股份有限公司（以下简称"公司"）全资子公司成大生物（本 溪）有限公司（以下简称"本溪子公司"）于近日收到国家药品监督管理局核准 签发的《药物临床试验批准通知书》（通知书编号：2026LP00405），批准流感病毒 裂解疫苗（高剂量）开展临床试验。鉴于疫苗产品研发周期较长、审批环节较多， 易受诸多不 ...